Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: January 28, 2016
Reporting Period: Fourth quarter and full year 2015
This filing announces the results of operations for the fourth quarter and full year 2015. Detailed financial data is contained in the press release furnished as Exhibit 99.1, which is incorporated by reference.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are located in the referenced Exhibit 99.1 (Press Release).
The company utilizes non-GAAP financial measures to assess performance, specifically:
- Net earnings from continuing operations excluding specified items.
- Exclusions for intangible amortization expense.
Material Changes and Adjustments
The filing details specific items excluded from non-GAAP measures to provide visibility on ongoing business performance. These adjustments include:
- Cost reduction initiatives.
- Transaction-related costs.
- Tax expense associated with a one-time repatriation of ex-U.S. earnings.
- Resolution of various tax positions and adjustments of tax uncertainties from prior years.
- Gain on the sale of a portion of Abbott's position in Mylan stock.
- Decrease in the fair value of contingent consideration related to a business acquisition.
Guidance, Outlook, and Management Commentary
Management states that non-GAAP measures are used internally to monitor business performance and provide investors with useful information regarding ongoing operations. However, the company cautions that these measures should be considered in addition to, and not as a substitute for, GAAP financial measures.
The filing text does not contain specific forward-looking guidance, risk factors, or contingencies beyond the standard caution regarding non-GAAP measures.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific GAAP and non-GAAP revenue, earnings, and cash flow figures.
- Verify the reconciliation between GAAP and non-GAAP net earnings, specifically regarding the Mylan stock sale gain and tax repatriation expenses.
- Assess the impact of intangible amortization exclusions on reported margins.
- Confirm the status of the contingent consideration related to recent business acquisitions.